Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease

Lexicon Pharmaceuticals, Inc. has announced the publication of new research findings on the biological effects of sotagliflozin in cardiovascular disease, emphasizing its therapeutic potential. The announcement does not include specific financial terms or clinical trial outcomes. This publication acts as a scientific update on the company's research pipeline.